JP2025515036A - ＰＩＫｆｙｖｅキナーゼ阻害剤 - Google Patents
ＰＩＫｆｙｖｅキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2025515036A JP2025515036A JP2024564691A JP2024564691A JP2025515036A JP 2025515036 A JP2025515036 A JP 2025515036A JP 2024564691 A JP2024564691 A JP 2024564691A JP 2024564691 A JP2024564691 A JP 2024564691A JP 2025515036 A JP2025515036 A JP 2025515036A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- virus
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263363962P | 2022-05-02 | 2022-05-02 | |
| US63/363,962 | 2022-05-02 | ||
| PCT/US2023/019770 WO2023215133A1 (en) | 2022-05-02 | 2023-04-25 | Pikfyve kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515036A true JP2025515036A (ja) | 2025-05-13 |
| JP2025515036A5 JP2025515036A5 (https=) | 2026-04-28 |
Family
ID=86604380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024564691A Pending JP2025515036A (ja) | 2022-05-02 | 2023-04-25 | ＰＩＫｆｙｖｅキナーゼ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250282767A1 (https=) |
| EP (1) | EP4519255A1 (https=) |
| JP (1) | JP2025515036A (https=) |
| WO (1) | WO2023215133A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL309445A (en) | 2021-06-22 | 2024-02-01 | Acurastem Inc | PIKFYVE antisense oligonucleotides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| KR20110017445A (ko) * | 2008-06-11 | 2011-02-21 | 아스트라제네카 아베 | 암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체 |
| US10758545B2 (en) | 2015-06-25 | 2020-09-01 | University Of Southern California | Methods to treat neurological diseases |
| CA3050021A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| JP2020505399A (ja) * | 2017-01-25 | 2020-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化合物 |
| WO2019046316A1 (en) | 2017-08-28 | 2019-03-07 | Acurastem Inc. | PIKFYVE KINASE INHIBITORS |
| JP7290651B2 (ja) * | 2018-02-07 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Ａｔｒ阻害剤及びその応用 |
| CN118619944A (zh) * | 2019-06-06 | 2024-09-10 | 北京泰德制药股份有限公司 | 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物 |
| WO2021163727A1 (en) | 2020-02-11 | 2021-08-19 | AcuraStem Incorporated | Pikfyve kinase inhibitors |
-
2023
- 2023-04-25 JP JP2024564691A patent/JP2025515036A/ja active Pending
- 2023-04-25 EP EP23726667.1A patent/EP4519255A1/en active Pending
- 2023-04-25 WO PCT/US2023/019770 patent/WO2023215133A1/en not_active Ceased
- 2023-04-25 US US18/862,354 patent/US20250282767A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519255A1 (en) | 2025-03-12 |
| WO2023215133A1 (en) | 2023-11-09 |
| US20250282767A1 (en) | 2025-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240352026A1 (en) | Pikfyve kinase inhibitors | |
| CN110437205B (zh) | 吡啶烯基哌啶衍生物及其用途 | |
| US20100137584A1 (en) | Fused heteroaryl derivatives | |
| CN113710276B (zh) | 苯二氮䓬衍生物作为rsv抑制剂 | |
| US20190002479A1 (en) | Heterocyclic compounds as rsv inhibitors | |
| WO2001083456A1 (en) | Condensed heteroaryl derivatives | |
| US11945830B2 (en) | Antiviral heterocyclic compounds | |
| CN113164475A (zh) | Dyrk1a的大环抑制剂 | |
| CN104254532A (zh) | 磷酸肌醇3-激酶抑制剂 | |
| WO2012142615A2 (en) | Auranofin and auranofin analogs useful to treat proliferative disease and disorders | |
| US20240197747A1 (en) | Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors | |
| CN111004214B (zh) | 吡啶酰基哌啶衍生物及其用途 | |
| US20250368659A1 (en) | Antiviral Heterocyclic Compounds | |
| CN110272425B (zh) | 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途 | |
| US20240368174A1 (en) | Antiviral Heterocyclic Compounds | |
| TW201805271A (zh) | 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途 | |
| JP2025515036A (ja) | ＰＩＫｆｙｖｅキナーゼ阻害剤 | |
| CN115485271B (zh) | 用作parp抑制剂的化合物 | |
| CN111187251B (zh) | 吡啶酰基哌啶衍生物及其用途 | |
| CN111187252A (zh) | 吡啶酰基氮杂螺庚烷衍生物及其用途 | |
| CN110845402B (zh) | 吡啶亚甲基哌嗪衍生物及其用途 | |
| US11179400B2 (en) | Heterocyclic compounds as RSV inhibitors | |
| CN114728929A (zh) | 吡啶亚甲基哌啶衍生物及其用途 | |
| US11534439B2 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors | |
| HK40105472A (zh) | 用作cdk4激酶抑制剂的化合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260420 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260420 |